1.74
Propanc Biopharma Inc (PPCB) 最新ニュース
PPCB Should I Buy - Intellectia AI
Propanc Biopharma (PPCB) Earnings Outlook: Key Metrics for Q3 2025Post-Announcement Reaction - Newser
PPCB Stock Price, Quote & Chart | PROPANC BIOPHARMA INC (NASDAQ:PPCB) - ChartMill
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade - The Manila Times
Propanc Biopharma to file CTA in Australia for phase 1b study in 30-40 advanced cancer patients - marketscreener.com
Propanc Biopharma, Inc. CEO Forecasts Medical Breakthroughs Against Pancreatic Cancer Over Next Decade - Quiver Quantitative
Propanc pancreatic cancer drug saw 3 of 4 patients outlive life expectancy - Stock Titan
Propanc engages CDMO for GMP manufacture of cancer drug PRP By Investing.com - Investing.com Australia
Propanc engages CDMO for GMP manufacture of cancer drug PRP - Investing.com UK
Propanc Biopharma engages European CDMO for GMP production of PRP - TipRanks
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 3040 Advanced Cancer Patients - The Manila Times
Once-weekly proenzyme cancer therapy nears first tests in humans - Stock Titan
Propanc Biopharma (PPCB) Stock: Up +21.18%, Key Resistance at $2.16 2026-05-18Sector Analysis - newser.com
Propanc Biopharma reports Q3 results, secures financing - Investing.com UK
Propanc Biopharma reports Q3 results, secures financing By Investing.com - Investing.com Nigeria
Propanc Biopharma, Inc. Reports Q3 Financial Results and Key Corporate Developments - Quiver Quantitative
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results - marketscreener.com
Propanc moves to world-first cancer trial and anti-aging research - Stock Titan
Propanc Biopharma, Inc. 3Q 2026: Revenue $0 Net loss $(6.36M), EPS $(0.28) — 10-Q Summary - TradingView
Propanc Biopharma (PPCB) posts Q3 2026 loss and flags going concern risk - Stock Titan
Propanc Biopharma to Implement 1-for-25 Reverse Stock Split >PPCB - Moomoo
Propanc Biopharma Implements Reverse Stock Split To Support Continued Nasdaq Listing And Growth Plans - TradingView
25 Propanc shares become 1 in Nasdaq bid-price compliance move - Stock Titan
Propanc Biopharma announces 1-for-25 reverse stock split By Investing.com - Investing.com Australia
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans - The Manila Times
Propanc Biopharma announces 1-for-25 reverse stock split - Investing.com
Propanc Biopharma, Inc. Announces 1-for-25 Reverse Stock Split to Enhance Nasdaq Compliance - Quiver Quantitative
Propanc Biopharma implements reverse stock split to support continued Nasdaq listing and growth plans - marketscreener.com
The supply chain story behind Propanc Biopharma (PPCB) earnings |Crowd Trend Signals - newser.com
Propanc Biopharma announces up to $100M strategic financing from Hexstone Capital - MSN
[EFFECT] Propanc Biopharma, Inc. SEC Filing - Stock Titan
Trending Industry Today: Propanc Biopharma Leads Gains In ETH-Holding Companies Stocks - Moomoo
Rosen Law Firm Encourages Propanc Biopharma Inc. Investors to Inquire About Securities Class Action Investigation – PPCB - The Joplin Globe
12 Health Care Stocks Moving In Wednesday's Intraday SessionAspire Biopharma Holdings (NASDAQ:ASBP), H - Benzinga
Propanc Biopharma Incfiles to offer resale of up to 15 million shares of common stock by selling stockholderSEC filing - marketscreener.com
Propanc Biopharma (PPCB) files S-1 for 15M-share resale from Series C preferred - Stock Titan
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
PPCB Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Propanc Biopharma (PPCB) approves restricted grants, reverse split 1:10–1:30 - Stock Titan
Propanc Biopharma, Inc. (PPCB) - Minichart
What should investors watch in Propanc Biopharma (PPCB) Stock | Price at $0.10, Down 3.30%Buy Signals - Newser
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain - BioSpace
Propanc extends 17-year Spain research tie to study aging and cancer - Stock Titan
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer - GlobeNewswire
大文字化:
|
ボリューム (24 時間):